EGFR and non-small cell lung carcinoma: Osimertinib has also demonstrated potent activity in T790M-positive NSCLC patients with CNS metastases who previously received EGFR-TKI therapy, with a median PFS of 8.4 months (95% CI = 5.8–10.9) and an ORR of 39.4%.